# A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

> **NCT00484939** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 280 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00484939
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484939, "A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00484939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*